me p	dRxiv preprint doi: https://doi.org/10.1101/2023.11.16.23298616; this version posted November 16, 2023. The copyright holder for this reprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .
1	PREDICTORS FOR PARTICIPATION IN MASS-TREATMENT AND FEMALE GENITAL
2	SCHISTOSOMIASIS RE-INVESTIGATION, AND THE EFFECT OF PRAZIQUANTEL TREATMENT IN
3	SOUTH AFRICAN ADOLESCENTS
4	Takalani Girly Nemungadi ^{1*} , Elisabeth Kleppa ² , Hashini Nilushika Galappaththi-Arachchige ² , Pavitra
5	Pillay³, Svein Gunnar Gundersen⁴, Birgitte Jyding Vennervald⁵, Patricia D. Ndhlovu⁰, Myra Taylor¹,
6	Saloshni Naidoo ¹ , Eyrun F. Kjetland ^{1,2}
7	
8	¹ Discipline of Public Health Medicine, College of Health Sciences, University of KwaZulu-Natal,
9	Durban, South Africa
10	² Norwegian Centre for Imported and Tropical Diseases, Oslo University Hospital, Oslo, Norway
11	³ Department of Biomedical and Clinical Technology, Durban University of Technology, KwaZulu-
12	Natal, South Africa
13	⁴ Institute for Global Development and Planning, University of Agder, Kristiansand, Norway
14	⁵ Section for Parasitology and Aquatic Pathobiology, Faculty of Health and Medical Sciences,
15	University of Copenhagen, Copenhagen, Denmark
16	⁶ BRIGHT Academy, Ugu District, South Africa
17	
18	[*] Corresponding author: Takalani Girly Nemungadi, University of KwaZulu-Natal, School of Nursing
19	and Public Health, Durban, South Africa, 4041 (Email: takalaninemungadi@gmail.com)
20	

Keywords. Female genital schistosomiasis; FGS symptoms; homogenous yellow patch; grainy sandy patch, mass drug administration, treatment. Note: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

21

Type of Article: Clinical Article

perpetuity. It is made available under a CC-BY 4.0 International license .

ABSTRACT

23 Objective

24 Female Genital Schistosomiasis (FGS) causes intravaginal lesions and symptoms that could be

25 mistaken for sexually transmitted diseases or cancer. In adults, FGS lesions are refractory to

26 treatment. The effect of treatment has never been explored in young women; it is unclear if

27 gynaecological investigation will be possible in this young age group (16 - 23 years). We

28 explored the predictors for accepting anti-schistosomal treatment and/or gynaecological

29 reinvestigation in young women, and the effects of anti-schistosomal mass-treatment

30 (praziquantel) on the clinical manifestations of FGS at an adolescent age.

31

32 Method

The study was conducted in randomly selected, rural, high schools in Ilembe, uThungulu and 33 Ugu Districts, KwaZulu-Natal Province, East Coast of South Africa. At baseline, after obtaining 34 35 ethical approval and informed consent, gynaecological investigations were conducted in female learners in grades 8 to 12 (aged 16-23 years). Mass-treatment was offered in the low-36 37 transmission season between May and August (a few in September), in accordance with WHO recommendations. Reinvestigation was offered after a median of 9 months (range 5-14 38 39 months). Univariate, multivariable and logistic regression analysis were used to measure the 40 association between variables.

41

42 Results

43 Of the 2293 learners who came for baseline gynaecological investigations, 1045 (46%) had signs of schistosomiasis, 209/1045 (20%) had grainy sandy patches; 208/1045 (20%) 44 homogenous yellow patches; 772/1045 (74%) had abnormal blood vessels; and 404/1045 45 (39%) were urine positive. Overall, only 26% (587/2293) learners participated in the mass 46 47 treatment and 17% (401/2293) participated in the follow up gynaecological reinvestigations. More than 70% of learners with FGS lesions were lost to follow-up: 156/209 (75%) grainy 48 sandy patches; 154/208 (74%) homogenous yellow patches; 539/722 (75%) abnormal blood 49 vessels; 238/404 (23%) urine positive. The grade 12 pupil had left school and did not 50 participate in the reinvestigations. Amongst those with lesions who came for both treatment 51 and reinvestigation, 12 (of 19) still had grainy sandy patches, 8 (of 28) had homogenous yellow 52 53 patches, and 54 (of 90) had abnormal blood vessels. Only 3 out of 55 remained positive for S. 54 haematobium ova. The low mass treatment uptake and huge loss to follow up among those 55 who had baseline FGS contributed to small sample size at follow up, to understand the effect of treatment. However, multivariable analysis showed that treatment had effect on the 56 57 abnormal blood vessels (adjusted odds ratio = 2.1, 95% Cl 1.1 – 3.9 and p 0.018). HIV, current 58 water contact, water contact as a toddler and urinary schistosomiasis influenced participation 59 in mass treatment. Grainy sandy patches, abnormal blood vessels, homogenous yellow 60 patches, previous pregnancy, current water contact, water contact as a toddler and father 61 present in the family were strongly associated with coming back for follow-up gynaecological investigation. 62

63

64 Conclusion

65 Compliance to treatment and gynaecological reinvestigation was very low. There is need to

66 embark on large scale awareness and advocacy in schools and communities before

67 implementing mass-treatment and investigation studies. Further investigations with large

sample size are needed in order to fully understand the effect of treatment on FGS lesions, 68 including the right timing for treatment. 69

- 70
- AUTHOR SUMMARY 71

72 Female genital schistosomiasis (FGS) is a neglected tropical disease and it affects many women and young girls in schistosomiasis endemic areas. A lot of research is still needed to 73 understand the characteristics of FGS, its prevention, as well as the timing for treatment. As 74 a result of the limited information, some women who suffer from FGS end up being diagnosed 75 as suffering from diseases such as human papilloma virus or other sexually transmitted 76 77 diseases. The study highlights issues that need to be taken into considerations when providing 78 treatment or conducting mass treatment for schistosomiasis and FGS or planning gynaecological investigations to inform FGS control programmes. In this study of adolescent 79 girls and young women of KwaZulu-Natal Province of South Africa, we sought to explore the 80 81 factors that influence participation in mass treatment and gynaecological investigation, and investigating the effect of praziguantel treatment on FGS. Factors that influenced 82 83 participation in mass treatment included HIV, current water contact, water contact as a toddler and urinary schistosomiasis. Factors that influenced participation in follow up 84 gynaecological investigation included grainy sandy patches, abnormal blood vessels, 85 homogenous yellow patches, previous pregnancy, current water contact, water contact as a 86 toddler and father present in the family. There was low uptake and huge loss to follow up for 87 mass treatment, and this contributed to small sample size for follow up gynaecological 88 investigations to understand the effect of treatment. However, multivariable analysis 89 90 showed that treatment had effect on the abnormal blood vessels and not on grainy sandy patches and homogenous yellow patches. 91

92

93

95 INTRODUCTION

Female Genital Schistosomiasis (FGS) is a complication of schistosomiasis that results from 96 trapped schistosome eggs, which damage tissues and organs (1,2). It is known to affect 97 98 females of all age groups. FGS has a complex disease manifestation spectrum, including lesions of the cervix and vagina (grainy sandy patches and homogenous yellow patches), 99 surface bleeding, abnormal blood vessels and rubbery papules (3,4). FGS has also been 100 associated with sub-fertility or infertility, ectopic pregnancy, spontaneous abortion, 101 102 premature birth, and increased susceptibility to HIV transmission and possibly progression. 103 Reports suggest that eggs are evenly distributed in the genital organs (2,5–7). There are many case reports of concurrent FGS with cervical intra-epithelial neoplasia and one paper to date 104 has shown lower Human Papillomavirus (HPV) clearance in FGS positive women or increased 105 106 susceptibility to HPV (3,8–12).

107

WHO recommends mass drug administration in schistosomiasis endemic schools for 108 109 prevention of morbidity, and studies indicate that early treatment may be necessary to prevent genital lesions in adulthood (13–15). In South Africa, there is no mass treatment or 110 mass drug administration programme for schistosomiasis and treatment is case-by-case 111 upon consultation by the affected individuals. The mass treatment that was conducted 112 between 1998 and 2001 in KwaZulu-Natal was discontinued due to resource constraints 113 114 (16,17). FGS is not known among most health care workers, clinicians and community 115 members and only approximately 160 gynaecologists were previously informed about FGS in South Africa (16–19). As a result, FGS is not considered a priority condition. There is therefore 116 limited data and research and this leads to a low index of suspicion by clinicians and FGS 117 lesions often being misclassified as sexually transmitted infections or cervical cancer (2,5,20-118 27). There have been efforts by authorities in South Africa to mobilise WHO-donated 119

praziguantel in order to implement the mass treatment as per the recommended WHO 120 strategy over the past years. However, this has been a challenge since, the donated 121 praziquantel is not registered in the country and is not permitted to be used (28). 122 123 Subsequently, treatment has been mobilised from within the country and mass treatment is 124 being planned for implementation (29). In order to prevent low uptake and to properly plan for the roll-out of the mass treatment, it is important to identify factors that will influence 125 participation, and to determine the effect of treatment on FGS symptoms. It is also important 126 to identify factors that will influence participation in gynaecological investigation in order 127 128 to improve treatment and other prevention and control measures as well as research information that will provide new knowledge. 129

130

Between 2011 and 2013, we conducted a follow-up study and sought to explore the feasibility of the implementation of mass drug administration and gynaecological investigations in school-going young women in rural KwaZulu-Natal, and to explore the effects on lesions and symptoms.

135 MATERIALS AND METHODS

Ethical considerations. The study was approved by the Biomedical Research Ethics 136 137 Committee (BREC), University of KwaZulu-Natal (Ref BF029/07), KwaZulu-Natal Department 138 of Health (Reference HRKM010-08) and the Regional Committee for Medical and Health Research Ethics (REC), South Eastern Norway. The ethical committees were aware that minors 139 were invited into the study and specifically approved independent minor consent without 140 parental consent. All study participants were offered anti-schistosomal treatment and, if 141 applicable, treatment for sexually transmitted diseases, and/or referral to the local health 142 143 system for treatment of HIV.

144

Study subjects and area. The study was conducted between 2011 and 2015 in the KwaZulu-145 Natal Province of South Africa. The participants were female learners aged 16 – 23 years, from 146 randomly selected high schools in Ilembe, uThungulu and Ugu Districts on the East Coast of 147 South Africa that had not undergone anti-schistosomal mass-treatment before the first 148 investigation as shown in Table 1. The participants were recruited from schools that were 149 classified as rural by the South African Department of Basic Education and were below the 150 151 altitude of 400 meters above sea level, with an estimated prevalence of S. haematobium of 152 10% or more based on an initial show of hands for red urine in Ugu District and a haematuria dipstick survey in Ilembe and uThungulu districts (30). Gynaecological examinations were 153 performed in two research clinics (North of Durban and South of Durban); virgins, pregnant, 154 155 and severely ill females were excluded. Schools with prevalence of less than 10% were excluded 156

medRxiv preprint doi: https://doi.org/10.1101/2023.11.16.23298616; this version posted November 16, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
 Table 1. Study design and practicalities, their rationale, and the potential unintended

157 consequences 158

Inclusion considerations	Reason
Participants included were 16 years and above, including Grade 12	In order to explore reversibility of lesions, we wished to invite young women at an earliest possible time for a gynaecological investigation. However, gynaecological investigations are not practically feasible before the age of 16 for cultural, legal and sometimes anatomical reasons (31). Average sexual debut age is 18.7 years in South Africa and many hide sexual debut from e.g. their parents and teachers for as long as they can (32,33).
	Moreover, some may be worried about the "loss of virginity" during speculum examination (34,35). Visual inspection of the cervix, fornices and vaginal surfaces before sexual debut may therefore be offensive to their sensibilities.
KwaZulu-Natal was chosen as the study area	Firstly, at this tender age, chances were high that these young women would be invited for their first gynaecological examination. Some amongst the pupils might be found to have been raped and a gynaecological examination might trigger psychological reactions. Therefore, we looked for a study area where psychologists and support centres would be available for study participants in a schistosomiasis endemic area. Secondly, there are more than 4,000 rural schools in KZN and we estimated that we would be able to reach the necessary sample size (36,37).
Although some young women with multiple lesions were treated at the clinic, most were not done immediately after examination at the clinic.	Treatment with praziquantel was done at schools, not at the research clinics for the following reasons: 1) Mass Drug Administration is recommended so that siblings and class mates are treated simultaneously (15) 2) Anti-schistosomal treatment with Praziquantel should be given in the low-transmission season (28,38) 3) Praziquantel may cause nausea and sometimes vomiting; if treatment had been done at clinic immediately after investigation, some learners might become car sick on the way from the clinic, it could potentially scare others from participating (15).

159

160

Questionnaires and clinical examinations. Group information, individual information and the 161 consent form procedure was done at the school over a 2-week-period. Consent forms and 162 parent information were distributed in advance (39-41). The investigation has been described 163 164 previously. Briefly, a questionnaire on water contact, reproductive history, genital and abdominal symptoms was administered individually to participants in isiZulu (the local 165 language) prior to gynaecological examination (30). Teachers would suggest days when it 166 would be suitable to fetch learners from schools to go to the research clinic. Teenagers had 167 indicated they were embarrassed to give urine in school so urine was collected only while 168

they were at the clinic. ^{It is made available under a CC-BY 40 International license and well-informed days, a female driver, trained and well-informed about the study, would pick up 4-13 participants (depending on the vehicle size) for the drive to the clinic for gynaecological examinations.}

172

Treatment. In accordance with the WHO policy for areas of high schistosomiasis endemicity, 173 mass treatment of participants and other learners in enrolled schools was carried out during 174 the winter season (low-transmission season) after the baseline gynaecological examination. 175 Treatment began after lunch to ensure that the children had eaten their free school lunches 176 177 before treatment and to save the costs on food for the programme. Depending on the size of 178 school, the treatment team comprised of 2-4 nurses and 2-4 assistants (27). Bread and bananas were distributed to learners who had not received a school lunch. Learners with 179 signed consent forms were weighed, and the number of praziguantel tablets was calculated 180 181 for the dose of 40 mg per kg of body weight. As described previously, a designated nurse directly observed all tablet ingestion by counting the number of tablets in each learner's hand 182 183 and watching for hand-to-mouth intake (27). The treatment team stayed in the school for an 184 hour after the last dose to allow learners to report any side effects. All learners, even the untreated, were allowed to come back for follow-up gynaecological examination. 185

186

Sample size calculation and statistical analyses. Demographic and clinical variables were explored as predictors for (1) participation in mass-treatment and (2) returning to a followup gynaecological investigation. We planned a study of independent cases and controls with 3 control(s) per case. Prior data indicated that the probability of coming back for a gynaecological investigation among those with FGS disease is 15%. If the true probability of FGS among those who do not return is 9%, we will need to study 318 FGS patients and 954 without FGS to be able to reject the null hypothesis that the exposure rates for the groups

	medRxiv preprint doi: https://doi.org/10.1101/2023.11.16.23298616; this version posted November 16, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
194	perpetuity. are equal with probability (power) 80%. The Type Lerror probability associated with this test
195	of this null hypothesis is 0.05. We will use an uncorrected chi-squared statistic to evaluate
196	this null hypothesis.
197	
198	In order to study simultaneously the impact of several variables, logistic regression analysis
199	was applied with a 5% significance level; as a general rule variables were included if the p-
200	value from the crude association was less than 0.2 and if the Spearman rank correlation
201	coefficient was below 0.7. Age was forced into the model.

202

- 203 To assess the overlap of the FGS lesions among the learners, we created Venn diagrams using
- 204 Venny version 2.1 (Juan Carlos Oliveros,
- 205 <u>https://bioinfogp.cnb.csic.es/tools/venny/index2.0.2.html</u>)

207 RESULTS

208 Description of the study population.

- 209 A total of 2293 adolescent girls and young women from 70 secondary schools were enrolled and
- 210 examined gynaecologically for FGS lesions at baseline. As shown in Figure 1, 1045/2293 (46%) learners
- 211 had genital lesions or signs of urinary schistosomiasis at baseline. None of them had rubbery papules.
- 212 Abnormal blood vessels were the most common findings.
- 213



215 Figure 1. Genital lesions and signs for schistosomiasis amongst adolescent girls and young

- women in Kwa-Zulu-Natal between 2012 and 2013. 216
- 217

214

- As shown in Figure 2, 271 learners had more than one FGS lesions while 556 had only one FGS 218
- lesion (ABV: abnormal blood vessels, GSP: grainy sandy patches, HYP: homogenous yellow 219
- patches). 220





Figure 2. Venn diagram showing an overlap of baseline FGS lesions among learners.

224

225 Mass treatment participation

Treatment with praziquantel (40mg/kg) was given in the low-transmission season (South African winter between May and August, including a few in September). Only 26% (587 of the 2293) learners were treated between baseline and follow-up. Multivariable analysis showed that HIV, current water contact, water contact as a toddler and urinary schistosomiasis positively influenced learners' willingness to participate in the mass treatment (Table 2). A greater loss to follow-up for mass treatment was observed in the Southern research clinic as compared to the Northern clinic (odds ratio = 2.1, 95% Cl 1.7 – 2.6 and p <0.001).

200

234

History	Participated in mass	Did not participate in		Univariate	e analysis	is Multivariable analysis			
	treatment (%) mass treatment (%) Odds		95% Confidence p-value		Adjusted	95%	p-value		
			ratio	Interval		odds ratio	Confidence Interval		
Grade 8	4/209 (2)	6/1026 (1)	1			1			
Grade 9	13/209 (6)	43/1026 (4)	0.9	0.3-2.6	0.913	0.7	0.2-2.3	0.600	
Grade 10	51/209 (24)	277/1026 (27)	0.6	0.2-1.5	0.274	0.4	0.2-1.2	0.113	
Grade 11	128/209 (61)	507/1026 (49)	0.6	0.3-1.7	0.389	0.5	0.2-1.5	0.249	
Grade 12	13/209 (6)	193/1026 (189)	0.9	0.3-2.3	0.813	0.6	0.2-0.7	0.346	
Current water contact	391/587 (59)	596/1050 (57)	1.5	1.2 – 1.9	< 0.001	1.4	0.1-1.8	0.003	
Urinary schistosomiasis	90/517 (17)	193/895 (22)	0.8	0.6 - 1.0	0.060	0.7	0.5-0.9	0.037	
Abnormal blood vessels	215/587 (37)	337/1050 (32)	1.2	0.9 – 1.5	0.063	1.1	0.8-1.3	0.680ª	
						1.1	0.9-1.4	0.245 ^b	
Water contact as toddler	339/587 (58)	611/1050 (58)	1.5	1.2 – 1.9	< 0.001	1.4	1.1-1.8	0.002	
HIV	86/555 (15)	210/999 (21)	0.7	0.5 – 0.9	0.008	0.7	0.5-0.9	0.015	
Red urine previously or now	155/587 (26)	320/1045 (31)	0.8	0.6 - 1.0	0.072	0.8	0.7-1.1	0.138	
Mother present in the family	375/587 (64)	625/1045 (60)	1.2	0.9 – 1.5	0.105	1.3	0.9-1.6	0.055	
Homogenous yellow patch	60/587 (10)	90/1050 (09)	1.2	0.9 – 1.7	0.267				
Has ever been pregnant	280/587 (48)	504/1050 (48)	0.9	0.8 – 1.2	0.907				
Heavy bleeding with clots	176/408 (43)	350/755 (46)	0.9	0.7 – 1.1	0.292				
Father present in the family	136/587 (23)	251/1045 (24)	0.9	0.8 – 1.2	0.698				
Genital itch	361/587 (61)	658/1046 (63)	0.9	0.8 – 1.2	0.573				
Genital burn	243/587 (41)	464/1046 (44)	0.9	0.7 – 1.1	0.246				
Genital sore/ulcer	114/585 (19)	206/1043 (20)	0.9	0.8 – 1.3	0.898				
Genital lump	93/583 (16)	176/1038 (17)	0.9	0.7 – 1.2	0.602				
Urge with leak	270/587 (46)	499/1045 (48)	0.9	0.8 - 1.1	0.496				
Urge	202/585 (35)	346/1044 (33)	1.1	0.9 – 1.3	0.569				
Dysuria	297/587 (35)	550/1044 (52)	0.9	0.8 - 1.1	0.418				
Bloody discharge	104/583 (17)	198/1043 (19)	0.9	0.7 – 1.2	0.569				
Watery discharge	369/583 (63)	638/1039 (61)	1.1	0.9 – 1.3	0.452				
Abnormal discharge smell	260/583 (45)	490/1042 (47)	0.9	0.7 – 1.1	0.346				
Grainy sandy patch	49/587 (08)	102/1050 (08)	0.8	0.6 - 1.2	0.359				

Table 2. Underlying factors and compliance with mass-treatment

^bmultivariable with abnormal blood vessels and current water contact, ^cmultivariable with abnormal blood vessels and water contact as a toddler.

Gynaecological reinvestigation 236

237	Table 3 shows that a total of 709 learners (31% of the 2293 learners) were interviewed at
238	follow up. Of the 709, 398 agreed to participate in the follow up gynaecological investigation;
239	the majority (32%) felt that they were not ready. The willing participants were reinvestigated
240	after a median of 9 months (range 5 - 14 months). The median age of those followed-up was
241	19 years (range 16 - 23 years), and those who were lost to follow-up had a median age of 18
242	years (range 16 – 23 years).

243

Table 3. Reasons for refusing follow up gynaecological examination (n=709) 244

Reasons for denying or aborting gynaecological examination	Came for	Came for follow up			
	No (%)	Yes (%)			
Did not deny or abort	16 (3.9)	398 (%)	414 (100)		
Fear	26 (100)	0 (0)	26 (100)		
Not ready	127 (100)	0 (0)	127 (100)		
Menstruation	24 (92)	2 (8)	26 (100)		
Virgin	14 (100)	0 (0)	14 (100)		
Pregnant	53 (100)	0 (0)	53 (100)		
Other	48 (98)	1 (2)	49 (100)		
TOTAL	308 (43)	401 (57)	709 (100)		

245

Table 4 show factors that may have contributed to compliance with follow up gynaecological 246 investigation. The three FGS lesions (grainy sandy patches, abnormal blood vessels and 247 homogenous yellow patches), previous pregnancy, current water contact, water contact as a 248 toddler and father present in the family were strongly associated with coming back for a 249 250 follow-up investigation in both univariate and multivariable analysis. Multivariable analysis of 251 the three FGS lesions individually (to account for a causal relationship) with current water 252 contact, previous pregnancy and water contact as a toddler had no effect on the association. A greater loss to follow-up for gynaecological investigation was observed in the Southern 253 research clinic as compared to the Northern clinic (odds ratio = 1.9, 95% Cl 1.5 - 2.4 and p 254 <0.001). 255

Table 4. Underlying factors associated with coming	g back for follow-up	gynaecological investigations
Table 1. Onderlying factors associated with coming	5 buck for follow up	Synaccological intestigations

History	Came for follow-up (%)	Did not come for		Univariate analysis		Multivariable analy		
		gynaecological	Odds	95% Confidence	p-value	Adjusted	95% Confidence	p-
		investigation	ratio	Interval		odds ratio	Interval	value
Grade 8	5/400 (1)	18/1863 (1)	1			1		
Grade 9	24/400 (7)	92/1863 (5)	0.9	0.3-2.8	0.910	0.8	0.3-2.5	0.724
Grade 10	120/400 (30)	488/1863 (26)	0.9	0.3-2.4	0.813	0.8	0.3-2.2	0.635
Grade 11	214/400 (54)	742/1863 (40)	1.0	0.4-2.8	0.941	0.9	0.3-2.5	0.803
Grade 12	37/330(6)	523/1863 (28)	0.3	0.1-0.7	0.010	0.2	0.1-0.6	0.004
Grainy sandy patch*	56/401 (14)	153/1892 (8)	1.8	1.3-2.6	<0.001	1.8	1.3-2.6	<0.001
Abnormal blood vessels*	185/401 (46)	537/1892 (28)	2.3	1.7-2.7	<0.001	2.2	1.7-2.7	<0.001
Homogenous yellow patch*	55/401 (14)	153/1892 (8)	1.8	1.3-2.5	<0.001	1.8	1.3-2.5	0.001
Has ever been pregnant	236/401 (60)	838/1892 (44)	1.8	1.4-2.2	<0.001	1.8	1.5-2.3	<0.001
Water contact as toddler	260/401 (65)	1119/1892 (59)	1.3	1.0-1.6	<0.034	1.4	1.1-1.7	0.009
Current water contact	257/401 (64)	1124/1892 (59)	1.2	0.9 - 1.5	0.082	1.4	1.1-1.7	0.012
Red urine previously or now	110/398 (28)	571/1883 (30)	0.9	0.7 – 1.1	0.287	0.8	0.6-1.1	0.140
Father present in the family	71/398 (19)	454/1881 (24)	0.7	0.5 – 0.9	0.007	0.7	0.5-0.9	0.010
Genital lump	65/394 (17)	311/1872 (17)	0.9	0.7 – 1.3	0.955			
Condom use	130/319 (41)	649/1604 (41)	1.0	0.8 - 1.3	0.923			
Heavy bleeding with clots	113/259 (44)	628/1403 (45)	0.9	0.7 – 1.2	0.736			
HIV	83/386 (22)	356/1794 (20)	1.1	0.8 - 1.4	0.461			
Mother present in the family	231/399 (58)	1136/1880 (60)	0.9	0.7 – 1.1	0.349			
Genital itch	253/399 (63)	1155/1884 (61)	1.1	0.9 – 1.4	0.433			
Genital burn	179/399 (45)	809/1884 (43)	1.1	0.9– 1.3	0.482			
Genital sore/ulcer	77/398 (19)	347/1879 (19)	1.1	0.8 - 1.4	0.682			
Urge with leak (urgenic1)	200/398 (50)	882/1883 (47)	1.1	0.9 – 1.4	0.216			
Urge but no leak (urge1)	137/392 (35)	639/1881 (34)	1.0	0.8 – 1.3	0.837			
Dysuria	217/398 (55)	982/1882 (52)	1.1	0.9 – 1.4	0.395			
Bloody discharge	70/397 (18)	356/1875 (19)	0.9	0.7 – 1.2	0.530			
Watery discharge	252/396 (64)	1168/1872 (62)	1.1	0.8 - 1.3	0.642			
Abnormal discharge smell	179/399 (45)	878/1869 (47)	0.9	0.7 – 1.1	0.442			
Urinary schistosomiasis	82/367 (22)	322/1579 (20)	1.1	0.9 – 1.5	0.407			

*Were analysed separately because some participants were affected by more than one lesion and there may be causal relationship between the three FGS lesions.

medRxiv preprint doi: https://doi.org/10.1101/2023.11.16.23298616; this version posted November 16, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity On the baseline investigation day, participants were informed about genital lesions (grainy sandy 256 patches, homogenous yellow patched and abnormal blood vessels) but urine microscopy results 257 258 were not readily available as the laboratory investigation were still going on. However, only approximately 25% of the young women with lesions returned for follow-up examinations (Figure 259 3, bold frame). As shown in Figure 3 (hatched frame), more than 70% of learners that had genital 260 lesions or signs of FGS at baseline were lost to follow up for gynaecological investigation, and 23% 261 of learners with urinary schistosomiasis were lost to follow-up. 262

263



- 265 Figure 3. Follow-up amongst adolescent girls and young women investigated for Female Genital
- 266 Schistosomiasis in Kwa-Zulu-Natal.
- 267 Legend:
- 268 Hatched frame: lost to follow-up for gynaecological investigation.
- 269 Bold frame: Remaining findings at follow-up gynaecological investigation
- 270

The effect of treatment 271

272

273	Multivariable analysis of the effect of treatment on baseline FGS showed that treatment only
274	had an effect on the abnormal blood vessels (adjusted odds ratio = 2.1, 95% Cl $1.1 - 3.9$ and
275	p 0.018) (Table 5). Treatment was protective against urinary schistosomiasis; only 3 learners
276	among the 55 that were treated remained positive for urinary schistosomiasis at follow up
277	(adjusted odds ratio = 0.4, 95% CI 0.01 – 0.1 and p < 0.001).

278

Before accounting for FGS lesions at baseline (including those with and without FGS lesions 279 at baseline), the univariate analysis showed a strong association between treatment and two 280 FGS lesions (homogenous yellow patches and abnormal blood vessels); at multivariable 281 analysis this association remained unchanged for the abnormal blood vessels (adjusted odds 282 ratio = 2.3, 95% CI 1.5 - 3.6 and p < 0.001) (Table 5) whereas it became insignificant for 283 284 homogenous yellow patches.

286	Table 5. Effect of treatment	 remaining FGS lesions amon 	g the treated and untreated
200			

FGS lesions	Treated (%)	Untreated		Univariate analysis			Multivariable anal		
		(%)	OR	95% CI	p-value	AOR	95% CI	p-	
								value	
	Effect of	treatment am	ong tl	nose with FG	S a baselir	ne			
Grainy sandy patches	12/19 (63)	23/34 (68)	0.8	0.3 – 2.7	0.741	0.5	1.1 – 2.1	0.369	
Homogenous yellow patches	08/28 (29)	03/26 (12)	3.1	0.7 – 3.2	0.120	6.7	0.9 - 48	0.058	
Abnormal blood vessels	54/90 (60)	40/93 (43)	1.9	1.1 - 3.6	0.022	2.1	1.1 – 3.9	0.018	
Urinary schistosomiasis	3/55 (5)	73/183 (53)	0.5	0.02 - 0.2	<0.001	0.4	0.01 - 0.1	<0.001	
Overall FGS rate a	t follow up (aft	er treatment a	nd inc	uding FGS a	mong thos	e who	did not have	FGS at	
			aselir	-					
Grainy sandy patches	25/167 (15)	35/229 (15)	0.9	0.6 - 1.7	0.931	0.9	0.5 – 1.7	0.903	
Homogenous yellow patches	24/167 (14)	17/229 (07)	2.1	1.1 - 4.0	0.025	1.8	0.9 – 3.5	0.096	
Abnormal blood vessels	81/167 (49)	66/229 (29)	2.3	1.5 – 3.5	<0.001	2.3	1.5 – 3.6	<0.001	
Urinary schistosomiasis	07/351 (02)	91/681 (13)	0.1	0.1 – 0.3	<0.001	0.1	0.1 – 0.3	<0.001	

288 DISCUSSION

The abnormal blood vessels were refractory to praziguantel treatment. Abnormal blood 289 290 vessels and grainy sandy patches were previously found to be significantly associated with 291 the presence of live worms as opposed to the homogenous yellow patches (42). The 292 association between praziguantel treatment and abnormal blood vessels may be an 293 indication that abnormal blood vessels are an early stage of the grainy sandy patches and are 294 easy to eliminate as opposed to the grainy sandy patches and homogenous yellow patches. It 295 is important to note that different investigators define the investigation findings differently and that the investigators of gynaecological examinations were different in baseline and 296 297 follow-up studies.

298

South Africa is not implementing mass drug administration (43); the remaining gynaecological 299 300 symptoms among the treated were high and may be an indication that for effectiveness, 301 several rounds of treatment are required and should be started at an earlier age. This 302 supports findings in Zimbabwe where a standard single-dose of praziguantel did not have effect on the inflammatory lesions of FGS that had formed and developed over a few years 303 (13). The timing for follow up investigations may have been too soon for some learners to 304 determine the true effect of treatment (the median time period between praziguantel 305 306 (40 mg/kg) treatment and reinvestigation was 5 months (range 5 – 14 months).

307

Treatment with praziquantel is the only recommended effective way of killing adult helminths and mature live eggs, but has no effect on the calcified ova; early treatment is therefore crucial before the ova are deposited in the tissue and cause damage (6,44). This may possibly explain the remaining gynaecological symptoms among the treated, including those who did

not have the lesions at baseline. A retrospective study found that treatment at an early age 312

313 seems to prevent gynaecologic morbidity (13).

314

315 Lack of a regular mass treatment programmes in South Africa, repeated exposure to risky water, and re-infections could have led to continuous FGS lesions even after a single dose of 316 praziquantel. Further investigations and follow up studies are therefore needed in countries 317 that are implementing mass drug administration and areas that are not implementing mass 318 319 drug administration. These studies will help with information to fully understand the 320 differences between the FGS lesions and whether praziquantel treatment can eliminate these lesions, including the right timing to possibly eliminate the lesions. Currently, only one study 321 has investigated the impact of treatment on gynaecological lesions and found no significant 322 323 change in the adult sandy patches and contact bleeding over a 12-month period, even though urinary egg excretion ceased (45). Another study found that schistosomiasis PCR remained 324 325 positive in the genitals after treatment (46). The lack of information and complexity in conducting research on how long it takes for the FGS lesions to manifest following infection 326 made it difficult to determine whether the FGS lesions diagnosed at follow-up were due to 327 schistosomiasis re-infection or were progressive lesions that had not yet manifested and 328 therefore diagnosed at baseline. Lack of a regular mass treatment programme in South Africa, 329 repeated exposure to risky water, and re-infections could have led to continuous FGS lesions 330 331 even after a single dose of praziquantel.

332

Identification of HIV, current water contact, water contact as a toddler and urinary 333 schistosomiasis as factors that influenced learners to participate in mass treatment are in 334 consistent with the general knowledge of the impact of these factors on schistosomiasis i.e. 335 schistosomiasis as a risk factor for HIV, and water contact as a risk for schistosomiasis. The 336

pre-treatment health education may have played a role in influencing these participants to 337 accept the treatment. Learners who felt they do not have a problem with these identified 338 339 factors may have perceived it unnecessary for them to get treated. Furthermore, the three 340 FGS lesions (grainy sandy patches, abnormal blood vessels and homogenous yellow patches), previous pregnancy, current water contact, water contact as a toddler and father present in 341 the family were strongly associated with returning for follow-up investigation. It is anticipated 342 that the investigators at the Northern clinic had gained more experience in both health 343 education and community engagement as opposed to when they conducted investigations at 344 345 the Southern clinic (the 1st investigation site) where there was a greater loss to follow up. Therefore, active ongoing community engagement targeting both learners, parents and the 346 entire community at risk is crucial in order to empower the community with the full 347 348 knowledge on prevention and control that will enable them to make informed decisions.

349

350 South Africa is endemic for schistosomiasis with some focal areas having high and moderate infections (42), and FGS studies among the young population may help identify targeted 351 interventions. Study findings revealed that more than 20% of the adolescent women in 352 KwaZulu-Natal province had three well-known genital mucosal manifestations of FGS (30); in 353 Limpopo Province, FGS accounted for 87.6% of the female cases in a study that described the 354 pathology of biopsy diagnosed schistosomiasis (47). However, treatment in South Africa is still 355 case-based and, as in many other countries, most community members do not seek early 356 treatment or do not seek treatment at all (17,27,48). Therefore, those infected and those that 357 complicate to FGS remain infected or with FGS complication; some individuals are 358 misdiagnosed as sexually transmitted infections (STIs) or cervical cancer (2,5,20–27). In this 359 study, loss to follow up was a major challenge. Involving community health workers in FGS 360 studies may assist with managing those who are lost to follow up because it would be easier 361

for them to maintain contact and follow up with the learners in their catchment area,

363 especially those found to have FGS symptoms.

364

362

365 It is important to note that gynaecological examination was not possible among the early and 366 middle adolescent group due to virginity, fear, pregnancy, and privacy and other related issues. Early adolescence and some middle adolescence may only be targeted for prevention 367 and only examined at the late adolescence stage to check if they developed any FGS after 368 369 repeated treatment. Observational studies in young adolescents and adults are critical in determining the effect of early treatment on schistosomiasis and FGS. It is similarly important 370 371 to determine the burden of infertility among those living in endemic areas and determine the association with FGS. Therefore, it is important for countries such as South Africa to establish 372 mass drug administration programmes in order to prevent sustained infections that can lead 373 374 to FGS.

375

376 The high loss to follow up is worrying because more knowledge is required through research to understand FGS pathogenesis and improve the knowledge of clinicians. For instance, it is 377 important to note that the high loss to follow during mass treatment in this study contributed 378 to small sample size to determine the effect of treatment on FGS. Currently, the lack of 379 380 knowledge of FGS among most clinicians and affected communities is concerning due to the 381 reported high prevalence of genital lesions (49). It has been reported that up to 75% of all 382 women and girls infected with urinary S. haematobium have lesions in the uterus, cervix, vagina or vulva (4). Many women have been reported to have genital schistosomiasis without 383 urinary excretion of S. haematobium eggs (2,4,13,50,51). In sub-Saharan Africa, it is estimated 384 that 56 million women have FGS (2). 385

386

387	In addition to the identified unintended consequences due to inclusion criteria and research
388	actions reported under results, the high loss to follow-up and low treatment coverage in this
389	study could also be attributed to factors that were reported by another study in South Africa
390	in Ugu Distict of KwaZulu-Natal Province. This Ugu District study was conducted among grade
391	10 – 12 learners, teachers, community health workers and traditional healers (16,17). Factors
392	that contributed to low coverage in this Ugu District study were reported to be:
393	• older age group;
394	lack of knowledge;
395	attending a large school
396	• parental control and a closer teacher follow-up in younger children and in small
397	schools;
398	• misconceptions that schistosomiasis is a self-healing disease and symptoms confused
399	with sexually transmitted infections;
400	 the chronicity of the disease is not known to the general population;
401	 teasing and stigma;
402	 schistosomiasis-related absenteeism that may reach 30% on some days;
403	• tablets must be distributed by health professionals in South Africa;
404	• schools reluctant to provide more than one day for treatment in order to minimise
405	disturbance (15,17,27).
406	The lower loss to follow up at the North of Durban clinic may be attributed to the experience
407	gained while operation at the first clinic (South of Durban). A praziquantel mass treatment
408	programme was implemented in South Africa, in Ugu District of KwaZulu-Natal Province
409	between 1998 and 2001 among grade 10 – 12 learners, teachers, community health workers

410 and traditional healers, and only reached 44% of the learners instead of the WHO and the

South African National Department of Health recommended target of 75% coverage (27). This shows a need to embark on large scale awareness and advocacy campaign in schools and communities, coordinated by the Department of Health and in collaboration with the Department of Basic Education, non-governmental organisations and community leaders, before implementing FGS studies among young people and mass treatment administration, to improve participation in research that will inform control measures.

417

418 Study limitations include the small sample size to determine the effect of treatment due to low treatment coverage and loss to follow up. Another limitation was that treatment was not 419 420 done immediately after baseline, and therefore many learners were not treated between 421 baseline and follow up either due to factors described above by Lothe *et al* in the qualitative studies in Ugu District, KwaZulu-Natal Province (16,17). As a result, some learners that were 422 not treated between baseline and follow up were only treated during follow-up. Some of the 423 learners under 16 years might already have had chronic lesions, and inclusion of the Grade 12 424 learners could have contributed to loss to follow up because of those who passed matric and 425 426 moved to tertiary institutions the following year.

427

In summary, it is critical to conduct vigorous ongoing community engagements for awareness and buy-in prior to mass treatment and gynaecological investigations in order to improve community participation. Because of the small sample size due to loss to follow-up, it is difficult to draw firm conclusions about the effect of treatment on FGS lesions.

432

433

perpetuity. It is made available under a CC-BY 4.0 International license .

436 AUTHOR CONTRIBUTION

437

- Takalani Girly Nemungadi conceived the presented idea, carried out the laboratory and statistical
 analysis, contributed to the writing and finalisation of the manuscript
- 440 Eyrun F. Kjetland helped conceive the presented idea, supervised the project, carried out statistical
- 441 analysis, contributed to the writing and finalisation of the manuscript
- 442 Saloshni Naidoo helped supervise the project and contributed to writing
- 443 Elisabeth Kleppa contributed to conceptualisation and writing
- 444 Hashini Nilushika Galappaththi-Arachchige contributed to conceptualisation and writing
- 445 Pavitra Pillay contributed to conceptualisation and writing
- 446 Svein Gunnar Gundersen contributed to conceptualisation and writing
- 447 Birgitte Jyding Vennervald contributed to conceptualisation and writing
- 448 Patricia Ndhlovu contributed to conceptualisation and writing
- 449 Myra Taylor contributed to conceptualisation and writing
- 450

451 ACKNOWLEDGMENTS

- 452 We are appreciative of the support from Roy Manyaira, Silindile Gagai and other staff at
- 453 BRIGHT Research in KwaZulu-Natal, South Africa. We thank all the girls and young women
- 454 who participated in the study.
- 455

CONFLICTS OF INTEREST

456 All authors report no conflicts of interest.

perpetuity. It is made available under a CC-BY 4.0 International license .

REFERENCES

Hegertun IEA, Sulheim Gundersen KM, Kleppa E, Zulu SG, Gundersen SG, Taylor 1. 458 M, et al. S. haematobium as a Common Cause of Genital Morbidity in Girls: A Cross-459 sectional Study of Children in South Africa. PLoS Negl Trop Dis. 2013;7(3):e2104 (1-460 461 8). 2. UNAIDS, World Health Organization. No more neglect. Female genital 462 schistosomiasis and HIV. Integrating reproductive health interventions to improve 463 women's lives [Internet]. Geneva, Switzerland; 2019 [cited 2020 Mar 12]. Available 464 from: 465 https://www.unaids.org/sites/default/files/media asset/female genital schistosomiasis 466 and hiv en.pdf 467 3. Kjetland EF, Norseth HM, Taylor M, Lillebø K, Kleppa E, Holmen SD, et al. 468 Classification of the lesions observed in female genital schistosomiasis. Int J Gynaecol 469 Obstet [Internet]. 2014;127:227-8. Available from: 470 http://www.scopus.com/inward/record.url?eid=2-s2.0-471 84906529324&partnerID=MN8TOARS 472 Kjetland EF, Gwanzura F, Ndhlovu PD, Mduluza T, Gomo E, Mason PR, et al. Simple 4. 473 474 clinical manifestations of genital Schistosoma haematobium infection in rural Zimbabwean women. Am J Trop Med Hyg [Internet]. 2005 Mar;72(3):311–9. 475 Available from: http://www.ncbi.nlm.nih.gov/pubmed/15772328 476 5. Christinet V, Lazdins-Helds JK, Stothard JR, Reinhard-Rupp J. Female genital 477 schistosomiasis (FGS): from case reports to a call for concerted action against this 478 neglected gynaecological disease. Int J Parasitol. 2016 Jun 1:46(7):395-404. 479 6. World Health Organisation. Ending the neglect to attain the Sustainable Development 480 Goals: A road map for neglected tropical diseases 2021–2030. Geneva, Switzerland: 481 World Health Organisation; 2020. 1–196 p. 482 7. Kjetland EF, Leutscher PDC, Ndhlovu PD. A review of female genital 483 484 schistosomiasis. Trends Parasitol [Internet]. 2012;28(2):58-65. Available from: 485 http://www.ncbi.nlm.nih.gov/pubmed/22245065 Eustace D, Trehan A, Raju KS, Derias N, Pambakian H. Abdominal pain and vaginal 8. 486 bleeding associated with schistosomiasis of the genital tract. J Obstet Gynaecol 487 (Lahore) [Internet]. 2009;12(6):427-8. Available from: 488 https://doi.org/10.3109/01443619209025953 489 9. Alalade AO, Leeson SC, Andrady U, An unusual association: Vulval schistosomiasis. 490 microinvasive vulval squamous cell carcinoma and high-grade vulval intraepithelial 491 neoplasia in HIV patient. Gynecol Surg. 2009;6(2):177-9. 492 493 10. Kjetland EF, Ndhlovu PD, Mduluza T, Deschoolmeester V, Midzi N, Gomo E, et al. 494 The effects of genital Schistosoma haematobium on human papillomavirus and the development of neoplasia after 5 years in a Zimbabwean population. A pilot study. Eur 495 J Gynec Oncol [Internet]. 2010/06/10. 2010;31(2):169-73. Available from: 496 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Cit 497 498 ation&list uids=20527233 11. Lalaina N, Irène RZ, Patrick M, Gabriël RP, Soa R. Schistosomiasis with Cervical 499 Cancer: About 2 Cases and Literature Review. Open J Pathol. 2021;11(01):1-6. 500 Kutz JM, Rausche P, Rasamoelina T, Ratefiarisoa S, Razafindrakoto R, Klein P, et al. 501 12. Female genital schistosomiasis, human papilloma virus infection, and cervical cancer 502 in rural Madagascar: a cross sectional study. Infect Dis poverty [Internet]. 503 2023;12(1):89. Available from: https://doi.org/10.1186/s40249-023-01139-3 504 13. Kjetland EF, Ndhlovu PD, Kurewa EN, Midzi N, Gomo E, Mduluza T, et al. 505 506 Prevention of gynecologic contact bleeding and genital sandy patches by childhood anti-schistosomal treatment. Am J Trop Med Hyg [Internet]. 2008/07/09. 2008 507

perpetuity. It is made available under a CC-BY 4.0 International license .

Jul;79(1):79–83. Available from: 508 509 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Cit 510 ation&list uids=18606767 World Health Organisation. Deworming adolescent girls and women of reproductive 14. 511 age: Policy brief [Internet]. 2021. Available from: 512 https://www.who.int/publications/i/item/9789240037670 513 15. World Health Organization. Helminth control in school-age children: A guide for 514 managers of control programmes. 2011. 515 Lothe A, Oyhus AO. Treating Bilharzia among High School Pupils. A study of 516 16. opportunities and constraints for treating Bilharzia among high school pupils in Ugu 517 district, South Africa. Vol. Masters, Faculty of Economics and Social Sciences. 518 [Development Management]: Agder University College; 2012. 519 Lothe A, Zulu N, Øyhus AO, Kjetland EF, Taylor M. Treating schistosomiasis among 17. 520 South African high school pupils in an endemic area, a qualitative study. BMC Infect 521 Dis. 2018:18(1):1-10. 522 Kukula VA, MacPherson EE, Tsev IH, Stothard JR, Theobald S, Gvapong M. A major 18. 523 hurdle in the elimination of urogenital schistosomiasis revealed: Identifying key gaps 524 525 in knowledge and understanding of female genital schistosomiasis within communities and local health workers. Hsieh MH, editor. PLoS Negl Trop Dis [Internet]. 2019 Mar 526 21 [cited 2019 Apr 2];13(3):e0007207. Available from: 527 528 http://dx.plos.org/10.1371/journal.pntd.0007207 529 19. Sommerfelt I, Ndhlovu P, Taylor M, Naidoo S, Pillay P, Haaland H, et al. Health professionals' knowledge about female genital schistosomiasis. A qualitative 530 531 investigation in a schistosomiasis endemic area in South Africa. SSM - Qual Res Heal [Internet]. 2023 Jun 1 [cited 2023 Jun 26];3:100292. Available from: 532 https://linkinghub.elsevier.com/retrieve/pii/S2667321523000768 533 534 20. Toller A, Scopin AC, Apfel V, Prigenzi KC, Tso FK, Focchi GR, et al. An interesting finding in the uterine cervix: Schistosoma hematobium calcified eggs. Autops Case 535 Rep [Internet]. 2015/10/21. 2015;5(2):41-4. Available from: 536 537 http://www.ncbi.nlm.nih.gov/pubmed/26484333 Mazigo HD, Samson A, Lambert VJ, Kosia AL, Ngoma DD, Murphy R, et al. "We 538 21. know about schistosomiasis but we know nothing about FGS": A qualitative 539 assessment of knowledge gaps about female genital schistosomiasis among 540 communities living in Schistosoma haematobium endemic districts of Zanzibar and 541 Northwestern Tanzania. Knopp S, editor. PLoS Negl Trop Dis [Internet]. 2021 Sep 30 542 [cited 2021 Oct 4];15(9):e0009789. Available from: 543 https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0009789 544 Engels D, Hotez PJ, Ducker C, Gvapong M, Bustinduy AL, Secor WE, et al. 22. 545 Integration of prevention and control measures for female genital schistosomiasis, HIV 546 547 and cervical cancer. Bull World Health Organ. 2020;98(9):615-24. Søfteland S, Sebitloane MH, Taylor M, Roald BB, Holmen S, 548 23. Galappaththi-Arachchige HN, et al. A systematic review of handheld tools in lieu of 549 colposcopy for cervical neoplasia and female genital schistosomiasis. Int J Gynecol 550 Obstet [Internet]. 2021 Feb 12 [cited 2021 Feb 9];153(2):190-9. Available from: 551 552 https://onlinelibrary.wiley.com/doi/10.1002/ijgo.13538 Norseth HM, Ndhlovu PD, Kleppa E, Randrianasolo BS, Jourdan PM, Roald B, et al. 553 24. The colposcopic atlas of schistosomiasis in the lower female genital tract based on 554 studies in Malawi, Zimbabwe, Madagascar and South Africa. PLoS Neglected Trop 555 556 Dis [Internet]. 2014 Nov;8(11):e3229 (1-17). Available from: http://europepmc.org/abstract/med/25412334 557 Mbabazi PS, Vwalika B, Randrianasolo BS, Roald B, Ledzinski D, Olowookorun F, et 25. 558 al. World Health Organisation Female genital schistosomiasis. A pocket atlas for 559 clinical health-care professionals [Internet]. Vol. 2015, WHO/HTM/NTD/2015.4. 560

	preprint	(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
504		perpetuity. It is made available under a CC-BY 4.0 International license .
561		Geneva: WHO; 2015. 1–49 p. Available from:
562	26	http://apps.who.int/iris/bitstream/10665/180863/1/9789241509299_eng.pdf
563	26.	Kjetland EF, Kurewa EN, Ndhlovu PD, Midzi N, Gwanzura L, Mason PR, et al.
564		Female genital schistosomiasis - a differential diagnosis to sexually transmitted
565		disease: Genital itch and vaginal discharge as indicators of genital <i>S. haematobium</i>
566		morbidity in a cross-sectional study in endemic rural Zimbabwe. Trop Med Int Heal.
567	27	2008;13(12):1509–17. Dan dialawia A. Erenna S.C. Munaami M. Kualawia ID. Zulu S.C. Casai S. et al. A
568	27.	Randjelovic A, Frønæs SG, Munsami M, Kvalsvig JD, Zulu SG, Gagai S, et al. A
569		study of hurdles in mass treatment of schistosomiasis in KwaZulu-Natal, South Africa.
570		South African Fam Pract [Internet]. 2015 [cited 2019 Jun 3];57(2):57–61. Available
571		from:
572		https://www.tandfonline.com/action/journalInformation?journalCode=ojfp20http://dx.
573	20	doi.org/10.1080/20786190.2014.978121
574	28.	Berge ST, Kabatereine NB, Gundersen SG, Taylor M, Kvalsvig JD, Mkhize-
575		Kwitshana Z, et al. Generic praziquantel in South Africa: The necessity for policy
576		change to avail cheap, safe and efficacious schistosomiasis drugs to the poor, rural
577		population. South Afr J Epidemiol Infect [Internet]. 2011 [cited 2013 Jan 26126(1):22.5. Available from http://gitei.co.go/index.ghp/SA JEJ/orticle/view/202
578	20	26];26(1):22–5. Available from: http://sajei.co.za/index.php/SAJEI/article/view/302
579	29.	National Department of Health. Schistosomiasis Mass Drug Administration Plan.
580	20	National Department of Health, South Africa; 2023. 1–31 p.
581	30.	Galappaththi-Arachchige HN, Holmen S, Koukounari A, Kleppa E, Pillay P,
582		Sebitloane M, et al. Evaluating diagnostic indicators of urogenital <i>Schistosoma</i>
583		<i>haematobium</i> infection in young women: A cross sectional study in rural South Africa.
584	21	PLoS One. 2018;13(2):1–15. Republic of South Africa, Children's Act. 2005, Covernment Cozotta, 28044 South
585	31.	Republic of South Africa. Children's Act, 2005. Government Gazette, 28944 South Africa: Government Gazette; 2006 p. 48.
586 587	32.	Nguyen VK, Eaton JW. Trends and country-level variation in age at first sex in sub-
588	52.	Saharan Africa among birth cohorts entering adulthood between 1985 and 2020. BMC
589		Public Health [Internet]. 2022;22(1):1–11. Available from:
590		https://doi.org/10.1186/s12889-022-13451-y
591	33.	Chartsbin. No Title [Internet]. [cited 2023 Jan 18]. Available from:
592	55.	http://chartsbin.com/view/xxj
593	34.	Mkasi L, Rafudeen A. Debating Virginity-testing Cultural Practices in South Africa: A
594	51.	Taylorian Reflection. J Study Relig [Internet]. 2016;29(2016):118–33. Available from:
595		http://www.scielo.org.za/pdf/jsr/v29n2/07.pdf
596	35.	Durojaye E. The human rights implications of virginity testing in South Africa. Int J
597	50.	Discrim Law. 2016;16(4):228–46.
598	36.	Department of Basic Education. School Masterlist Data [Internet]. March 2017.
599	201	Quarter 4 of 2016. Pretoria; 2017. Available from:
600		https://www.education.gov.za/Programmes/EMIS/EMISDownloads.aspx
601	37.	Livingston M, Pillay P, Zulu SG, Sandvik L, Kvalsvig JD, Gagai S, et al. Mapping
602		Schistosoma haematobium for novel interventions against Female Genital
603		Schistosomiasis and associated HIV risk in KwaZulu-Natal, South Africa. Am J Trop
604		Med Hyg. 2021;104(6):2055–2064.
605	38.	National Department of Health. Elimination of Schistosomiasis and Soil Transmitted
606		Helminths as Public Health Problems in South Africa. 2010. p. 1–48.
607	39.	Kleppa E, Ramsuran V, Zulu S, Karlsen GH, Bere A, Passmore J-A, et al. Effect of
608		Female Genital Schistosomiasis and anti- schistosomal treatment on monocytes, CD4+
609		T-cells and CCR5 expression in the female genital tract. PLoS One [Internet].
610		2014;9(6):e98593 (1-9). Available from: http://europepmc.org/abstract/med/24896815
611	40.	Kleppa E, Klinge KF, Galaphaththi-Arachchige HN, Holmen SD, Lillebø K, Onsrud
612		M, et al. Schistosoma haematobium Infection and CD4+ T-cell levels: A cross-
613		sectional study of young South African women. PLoS One. 2015;10(3):1-9.

- Kleppa E, Holmen SD, Lillebø K, Kjetland EF, Gundersen SG, Taylor M, et al. 41. 614 615 Cervical ectopy: associations with sexually transmitted infections and HIV. A cross-616 sectional study of high school students in rural South Africa. Sex Transm Infect. 2015:91:124-9. 617 42. Nemungadi TG, Furumele TE, Gugerty MK, Djirmay AG, Naidoo S, Kjetland EF. 618 Establishing and Integrating a Female Genital Schistosomiasis Control Programme 619 into the Existing Health Care System. Trop Med Infect Dis 2022, Vol 7, Page 382 620 621 [Internet]. 2022 Nov 16 [cited 2022 Nov 21];7(11):382. Available from: https://www.mdpi.com/2414-6366/7/11/382/htm 622 South African National Department of Health. Regular treatment of school-going 623 43. childen for soil-transmitted helminth infections and Bilharzia: Policy and 624 implementation guidelines. Pretoria, South Africa: The South African National 625 Department of Health; 2008 p. 38. 626 44. van Bogaert L. Case of invasive adenocarcinoma of the cervix in a human 627 immunodeficiency virus and schistosome co-infected patient. South African J 628 Gynaecol Oncol. 2014;6(1):5-6. 629 45. Kjetland EF, Mduluza T, Ndhlovu PD, Gomo E, Gwanzura L, Midzi N, et al. Genital 630 schistosomiasis in women: a clinical 12-month in vivo study following treatment with 631 praziguantel. Trans R Soc Trop Med Hyg [Internet]. 2006;100(8):740-52. Available 632 from: http://www.ncbi.nlm.nih.gov/pubmed/16406034 633 Downs JA, Kabangila R, Verweij JJ, Jaka H, Peck RN, Kalluvya SE, et al. Detectable 634 46. urogenital schistosome DNA and cervical abnormalities 6 months after single-dose 635 praziguantel in women with Schistosoma haematobium infection. Trop Med Int Heal 636 637 [Internet]. 2013/08/14. 2013;18(9):1090-6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23937701 638 47. van Bogaert LJ. Schistosomiasis - an endemic but neglected tropical disease in 639 640 Limpopo, Vol. 100, South African Medical Journal, 2010, p. 788–9. 48. Feldmeier H, Poggensee G, Krantz I. A synoptic inventory of needs for research on 641 women and tropical parasitic diseases. II. Gender-related biases in the diagnosis and 642 643 morbidity assessment of schistosomiasis in women. Acta Trop [Internet]. 1993/11/01. 1993 Nov:55(3):139-69. Available from: 644 http://www.ncbi.nlm.nih.gov/pubmed/7903838 645 49. Kukula VA, MacPherson EE, Tsey IH, Stothard JR, Theobald S, Gyapong M. A major 646 hurdle in the elimination of urogenital schistosomiasis revealed: Identifying key gaps 647 in knowledge and understanding of female genital schistosomiasis within communities 648 and local health workers. Hsieh MH, editor. PLoS Negl Trop Dis. 2018 649 650 Mar;13(3):e0007207. Bland KG, Gelfand M. The effects of schistosomiasis on the cervix uteri in the African 50. 651 female. J Obstet Gynaecol Br Commonw [Internet]. 1970/11/01. 1970;77(11):1127-652 31. Available from: http://www.ncbi.nlm.nih.gov/pubmed/5493619 653 Poggensee G, Kiwelu I, Saria M, Richter J, Krantz I, Feldmeier H. Schistosomiasis of 654 51. the lower reproductive tract without egg excretion in urine. Am J Trop Med Hyg 655 [Internet]. 1998;59(5):782–3. Available from: http://www.ncbi.nlm.nih.gov/htbin-656 post/Entrez/query?db=m&form=6&dopt=r&uid=0009840597 657 658
- 659